Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379963 | 0.80 | CA2 (0.56) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL28134157 | 0.80 | CA2 (0.56) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL3371941 | 0.77 | CA2 (0.53) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL10686709 | 0.74 | ALDH1A1 (0.38) | CA2ALDH1A1CYP1A2PARP15TNKS2 | |
| SCHEMBL28389963 | 0.74 | PSMB8 (0.37) | CA2HDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL30638470 | 0.74 | MGLL (0.53) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL28660108 | 0.74 | MGLL (0.53) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL29196077 | 0.72 | CA2 (0.53) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL4847352 | 0.72 | CA2 (0.49) | CA2ALDH1A1MEN1KMT2ADNMT1 | |
| SCHEMBL2000530 | 0.72 | BCL2L1 (0.55) | CA2ALDH1A1MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7410996-B2 | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-08-03 | — | — | US | disclosed |
| US-7037932-B2 | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1397129-B1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1587782-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | Eli Lilly and Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1587781-A1 | 3-ARYLOXY/THIO-2,3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004043904-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043903-A1 | 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1397129-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094262-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ADRB3, HTR3C, CHRNB3 | CA2 2036/4885ALDH1A1 1632/4885MEN1 742/4885 |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ADRB3, SLC6A3, SLC6A2 | CA2 2048/4885ALDH1A1 796/4885MEN1 2334/4885 |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ADRA2C, ADRB1, TPH1 | CA2 2775/4885ALDH1A1 292/4885MEN1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.